Format

Send to

Choose Destination
J Med Chem. 1989 Apr;32(4):880-4.

A minor modification of residue 1 in potent vasopressin antagonists dramatically reduces agonist activity.

Author information

1
Department of Peptide Chemistry, Smith Kline & French Laboratories, King of Prussia, Pennsylvania 19406.

Abstract

[1-(beta,beta-Pentamethylene-beta-mercaptopropionic acid),2-(O-ethyl)-D- tyrosine,4-valine,9-desglycine]arginine-vasopressin (SK&F 101926, 1), a potent in vivo and in vitro vasopressin V2 receptor antagonist, was recently tested in human volunteers and shown to be a full antidiuretic agonist. A new animal model for vasopressin activity has been developed in dogs that duplicates the clinical agonist findings exhibited with SK&F 101926. In this model we have discovered that substitution of a cis-4'-methyl group on the Pmp moiety at residue 1 of vasopressin antagonists results in substantially reduced agonist activity compared to the unsubstituted molecule (SK&F 101926). The corresponding analogue with a trans-4'-methyl group exhibits more agonist activity than the cis molecule. These findings can be explained by viewing the biological activities of compounds such as 1 as the interaction of the vasopressin receptor with a number of discrete molecular entities, conformers of 1, which present different pharmacophores. Models have been developed to assist in the understanding of these results.

PMID:
2522994
DOI:
10.1021/jm00124a025
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center